Method for increasing lipid content in microorganisms and modified microorganisms therefrom

Abstract

The present disclosure relates to a method for increasing lipid content in microorganisms. The method comprises decreasing the expression of molecules involved in the protein synthesis to decrease protein synthesis and thereby increase lipid synthesis in the microorganisms. The present disclosure also provides a modified microorganism having increased lipid content.

Claims

1. A method for increasing the lipid content in a photosynthetic microorganism, said method characterized by the following steps: a. obtaining a knock-out gene construct for inactivating initiator tRNA Met2 gene; b. cloning said knock-out gene construct in a vector comprising a selectable marker; c. introducing said vector containing the knock-out gene construct into a photosynthetic microorganism; and d. growing said photosynthetic microorganism under conducive conditions, wherein the conducive conditions comprise a medium containing the selectable marker and a pre-determined temperature for growth of the photosynthetic microorganism and obtaining said microorganism with increased lipid content.

2. The method as claimed in claim 1, wherein said photosynthetic microorganism is an alga.

3. The method as claimed in claim 2, wherein said alga, is Chlamydomonas.

4. The method as claimed in claim 1, wherein said knock-out gene construct comprises 1 kb flanking sequences of initiator tRNA Met2 gene.

5. The method as claimed in claim 1, wherein said vector is tRNA-Met2 deletion.

6. The method as claimed in claim 1, wherein said selective marker is at least one antibiotic selected from the group consisting of kanamycin, ampicillin and chloramphenicol.

7. A method for manufacturing a modified photosynthetic microorganism having increased lipid content, said method characterized by the following steps: a. obtaining a knock-out gene construct for inactivating initiator t RNA gene; b. cloning said knock-out gene construct in a vector; c. introducing said vector containing the knock-out gene construct into a photosynthetic microorganism; and d. growing said photosynthetic microorganism on a medium under conducive conditions, wherein the conducive conditions comprise a medium containing a selectable marker and a predeterimined temperature for growth of the photosynthetic microorganism to obtain the microorganism having increased lipid content, wherein the lipid content synthesized/produced by the modified microorganism is increased relative to the unmodified microorganism.

8. A modified photosynthetic microorganism manufactured by the method as claimed in claim 7.

9. The method as claimed in claim 7, wherein said photosynthetic microorganism with increased lipid content belongs to a strain of Synechococcus elongatus PCC 7942 having CCAP Accession Number 1479/17.

10. The method as claimed in claim 1, wherein said photosynthetic microorganism is cyanobacteria.

11. The method as claimed in claim 10, wherein the cyanobacteria is Synechococcus.

12. The method as claimed in claim 7, wherein said photosynthetic microorganism is an alga.

13. The method as claimed in claim 12, wherein said alga is Chlamydomonas.

14. The method as claimed in claim 7, wherein said photosynthetic microorganism is cyanobacteria.

15. The method as claimed in claim 14, wherein the cyanobacteria is Synechococcus.

Description

BRIEF DESCRIPTION OF THE ACCOMPANYING DRAWINGS

(1) The method of the present disclosure will now be described with the help of the accompanying drawings, in which:

(2) FIG. 1 illustrates a schematic process for increasing the lipid content in microorganisms by decreasing (down regulating) the protein synthesis in microorganisms;

(3) FIG. 2 illustrates the tRNA-Met2_deletion vector containing the knock-out gene construct prepared by deleting the initiator tRNA met2;

(4) FIG. 3 illustrates the PCR confirmation of the transformants prepared in accordance with the present disclosure;

(5) FIG. 4A illustrates the graphical representation of fluorescence observed for Chlamydomonas reinhardtii CW-15 cells (Day 4) in Tris Acetate Phosphate medium grown with and without cycloheximide using Nile Red Assay;

(6) FIG. 4B illustrates Nile Red stained Chlamydomonas reinhardtii CW-15 cells grown in the absence of cycloheximide;

(7) FIG. 4C illustrates Nile Red stained Chlamydomonas reinhardtii CW-15 cells grown in the presence of cycloheximide;

(8) FIG. 5 illustrates the spot inoculation of Synechococcus elongatus PCC 7942 (with the tRNA Met2 gene knocked out) on a medium containing a selective agent; and

(9) FIG. 6 depicts a graph illustrating the increase in lipid content in the modified strains of Synechococcus elongatus PCC 7942 as compared to the wild type.

DETAILED DESCRIPTION

(10) A major amount of fixed carbon from photosynthesis is channeled to the production of proteins. Hence, decreased protein synthesis would lead to utilization of this fixed carbon in making lipids, which can be used for the production of biofuels from the microorganisms, specifically from algae/cyanobacteria. The protein synthesis can be down-regulated and the carbon flux is redirected to the production of lipids.

(11) It is observed that the initiator tRNA molecules or initiation factor proteins/ribosomal RNA present in microorganisms are responsible for initiation of protein synthesis. It is possible to decrease the amounts of cellular initiator tRNA molecules by genetic modification of the microorganisms so that the protein synthesis would be decreased.

(12) Therefore, decreasing the availability of proteins by decreasing the rate of initiation of protein synthesis in microorganisms would lead to increased lipid content in the microorganisms. This would lead to increased biofuel production from these microorganisms.

(13) Therefore, in accordance with the present disclosure there is envisaged a method for decreasing (down regulating) protein synthesis in microorganisms, specifically in algae and cyanobacteria (as depicted in FIG. 1). The decrease in protein synthesis in the transformants would lead to utilization of the fixed carbon for the synthesis of lipid.

(14) In an aspect of the present disclosure, there is provided a method for decreasing (down regulating) protein synthesis and thereby increasing the lipid content in microorganisms.

(15) Chemical inhibition of protein synthesis is carried out using cycloheximide. Chlamydomonas reinhardtii CW-15 (Chlamydomonas Resource Center, USA), is grown in the presence of varying amounts of cycloheximide (50 M to 500 M) to find out the effect of inhibition of protein synthesis on lipid content. It is found that the chemical inhibition of protein synthesis results in an increase in lipid content (FIG. 4A). Highest lipid content is observed when the Chlamydomonas reinhardtii CW-15 cells are grown in the presence of 50 M of cycloheximide. When higher amounts of cycloheximide (more than 200 M) are used, a decrease in the lipid content is observed as illustrated in FIG. 4A. FIGS. 4B and 4C depict the Nile Red stained cells of Chlamydomonas reinhardtii CW-15 cells grown without the protein inhibitor and in the presence of the protein inhibitor, respectively. As seen from the FIG. 4C, an increase in the fluorescence is observed when the cells are grown in the presence of the protein inhibitor (cycloheximide), indicating an increase in the lipid content of the Chlamydomonas reinhardtii CW-15 cells as compared to the Chlamydomonas reinhardtii CW-15 cells grown in the absence of the protein inhibitor.

(16) Transfer RNA Met1 and tRNA Met2 are two initiator tRNA genes present in cyanobacteria and both are involved in the regulation of protein synthesis. In accordance with the present disclosure, tRNA Met2 gene is knocked out. A knock-out gene construct in accordance with the present disclosure is prepared by taking out 1 kb flanking sequences of the initiator tRNA gene and cloning in a vector containing a selective marker. In an embodiment of the present disclosure the selective marker is an antibiotic selected from the group including but not limited to kanamycin, ampicillin and chloramphenicol.

(17) In accordance with another aspect of the present disclosure, there are provided modified strains of microorganism, specifically modified strains of algae and/or cyanobacteria having increased lipid content, particularly, a modified strain in accordance with the present invention can be Synechococcus elongatus PCC 7942 deposited in the Culture Collection of Algae and Protozoa (CCAP), SAMS Limited, Scottish Marine Institute, Dunbeg, Oban, Argyll, PA37 1QA, UK and having CCAP Accession Number 1479/17.

(18) The present disclosure is further described in light of the following laboratory experiments which are set forth for illustration purposes only and not to be construed for limiting the scope of the disclosure.

EXPERIMENT 1:

Transformation of Synechococcus elongatus Pcc 7942

(19) One kilo base flanking sequences of the initiator tRNA (tRNA Met2) was taken out and then cloned into a vector containing an antibiotic (chloramphenicol) selection marker. The vector used in the present disclosure is tRNA-Met2_deletion. This vector was then used to knock-out the methionine tRNA (tRNA Met2) from Synechococcus elongatus PCC 7942.

(20) Synechococcus elongatus PCC 7942 (Institut Pasteur, France) was inoculated into 50 ml of BG-11 Basal Solution (HiMedia) and allowed to grow overnight at 30 C. till an OD.sub.730 of 1 (approximately 10.sup.8 cells/ml) was obtained. The culture was centrifuged at 4000 rpm and the pellet obtained was collected for further experiments.

(21) The pellet was washed thrice with 10 ml of ice cold 1 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer having pH 7.5. The pellet was soaked in the HEPES buffer for 5 minutes during each washing step.

(22) The supernatant was removed and the pellet was suspended in 500 l of HEPES buffer containing 6% dimethyl sulfoxide (DMSO) and 10% glycerol and mixed properly by vortexing to obtain a cell mixture.

(23) Hundred microliters of the above cell mixture was transferred into a pre-chilled Electroporation Cuvette. Five micro grams of linear DNA (dissolved in water) was added to the Electroporation Cuvette. One cuvette not having DNA was used as the control. The outside of the cuvette was completely dried and then placed in a Gene Pulser for electroporation. The electroporation parameters used in the present disclosure are given below: i) Field strength 1800 V/cm ii) Capacitance 25 F iii) Resistance 200 iv) Exponential decay wave pulse

(24) After completion of electroporation, the cuvettes were immediately incubated in ice for 5 minutes. The cells were then suspended in 1 ml of BG-11 Basal Solution and then inoculated in an Erlenmeyer flask containing 20 ml of BG-11 Basal Solution. The cells were incubated for 5 days at 30 C. under white light.

(25) After 5 days the cells were collected by centrifugation. The pellet obtained was suspended in 200 l of BG-11 Basal Solution. The culture was inoculated on BG-11 Basal Solution containing 1% agar and chloramphenicol. Colonies were observed on the plates after 20 days (FIG. 5A). Single colony was further propagated in liquid and solid BG-11 medium containing chloramphenicol for 8 generations for homoplasmicity.

(26) The transformation was confirmed by PCR using Chloramphenicol Acetyltransferase (CAT) gene primers as illustrated in FIG. 3. The DNA was isolated using Sigma plant DNA extraction kit and the genomic DNA was used as the template. From left to right: Lane-1 depicts the wild type, Lane-6 depicts the positive control containing pMet2 KO plasmid DNA, Lane-7 depicts the negative control without any DNA and Lane-8 depicts the 1 kb plus ladder marker (Thermo Scientific). Lane-2, Lane-3, Lane-4 and Lane-5 are the different transformants: Clone-1, Clone-3, Clone-4 and Clone-19, respectively prepared in accordance with the present disclosure. The vector tRNA-Met2_deletion has a size of 4775 bp. The arrow pointing to the band on Lane-6 (positive control), corresponds to 660 bp of the CAT gene. The wild type genomic DNA does not have a CAT gene and hence, no PCR product is observed after PCR and hence, there is no band corresponding to the wild type (Lane-1) as illustrated in FIG. 3. In the transformants, the tRNA Met2 gene was knocked-out and replaced with the CAT gene (660 bp). The arrows pointing to the bands in Lane-5 (Clone-19), Lane-4 (Clone-4) and Lane-3 (Clone-3) correspond to the CAT gene, confirming the transformation. The second band on Lane-2 is a non-specific band formed due to the PCR condition.

EXPERIMENT 2:

Comparison of the Lipid Produced by the Wild Type and the Transformants

(27) Ten milligram of dry mass of the wild type and the transformants were used for performing GC analysis of Octadecanoic acid, methyl ester (C18:0) produced. The amount (in %) of C18:0 produced by the wild type and the transformants (Clone-3 and Clone-19) are given in FIG. 6 and Table-1.

(28) Octadecanoic acid, methyl ester (C18:0) produced by the wild type and two transformants (Clone-3 and Clone-19) were compared as illustrated in FIG. 6. A 31% increase in the amount of lipid (C18:0) produced was observed for Clone-19 as compared to the wild type.

(29) TABLE-US-00001 TABLE 1 10 mg of dry mass % C18:0 WT 11.83 Clone-3 14.47 Clone-19 15.54

(30) It is clear from FIG. 6 and Table-1 that the transformants (clone-3 and clone-19) show an increase in the lipid content as compared to the wild type, indicating that the down regulation of protein synthesis results in an overall increase of lipid content in the transformants.

(31) Technical Advancements

(32) The technical advancements offered by the present disclosure are as follows: The present disclosure provides a method for decreasing (down regulating) the different molecules involved in protein synthesis to decrease the protein synthesis and hence, increase the lipid content of the microorganism. The present disclosure provides a method for increasing the lipid content of microorganisms to obtain increased production of biofuels. The present disclosure provides modified microorganisms with increased lipid content as compared to the wild type.

(33) The embodiments as described herein above, and various features and advantageous details thereof are explained with reference to the non-limiting embodiments in the description. Descriptions of well-known aspects, components and molecular biology techniques are omitted so as to not unnecessarily obscure the embodiments herein.

(34) The foregoing description of specific embodiments will so fully reveal the general nature of the embodiments herein, that others can, by applying current knowledge, readily modify and/or adapt for various applications of such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein. Further, it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.

(35) Having described and illustrated the principles of the present disclosure with reference to the described embodiments, it will be recognized that the described embodiments can be modified in arrangement and detail without departing from the scope of such principles.

(36) While considerable emphasis has been placed herein on the particular features of this disclosure, it will be appreciated that various modifications can be made, and that many changes can be made in the preferred embodiment without departing from the principles of the disclosure. These and other modifications in the nature of the disclosure or the preferred embodiments will be apparent to those skilled in the art from the disclosure herein, whereby it is to be distinctly understood that the foregoing descriptive matter is to be interpreted merely as illustrative of the disclosure and not as a limitation.